Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Amer H. Zureikat, Ibrahim Nassour, David L Bartlett, Annissa Desilva, Lance A. Liotta, Aatur D. Singhi, Virginia Espina, Alessandro Paniccia, Samer AlMasri, Nathan Bahary, Brian A. Boone, Herbert J. Zeh, Patricia Loughran, Michael T. Lotze, Mazen S. Zenati
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be safe and effective in inducing a serum biomarker response and increase resection rat
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Amer H. Zureikat, Alessandro Paniccia, James F. Pingpank, Samer AlMasri, Stacy J. Kowalsky, Haroon A. Choudry, Ibrahim Nassour
Publikováno v:
Annals of Surgical Oncology. 28:8916-8925
BACKGROUND Appendiceal goblet cell adenocarcinomas (GCC) are rare tumors with clinical behavior between classic carcinoids and adenocarcinomas. Current guidelines recommend right hemicolectomy for all GCCs. PATIENTS AND METHODS The National Cancer Da
Autor:
Sidrah Khan, Caroline J. Rieser, Richard S. Hoehn, Samer Tohme, Ibrahim Nassour, David S. Medich, Amer H. Zureikat, Lindsay M. Sabik, Katherine Hrebinko
Publikováno v:
J Surg Res
Background Safety-net hospitals serve a vital role in society by providing care for vulnerable populations. Existing data regarding oncologic outcomes of patients with colon cancer treated at safety-net hospitals are limited and variable. The objecti
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Nathan Bahary, Mazen S. Zenati, M.E. Hogg, Asmita Chopra, Herbert J. Zeh, David L. Bartlett, Joal D. Beane, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 28:7759-7769
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Ibrahim Nassour, Kenneth K. Lee, Samer Tohme, Christof Kaltenmeier, Sidrah Khan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Richard S. Hoehn, Katherine Hrebinko
Publikováno v:
Pancreas
Objectives The objective of this study was to create a composite measure, optimal oncologic surgery (OOS), for patients undergoing distal pancreatectomy for pancreatic adenocarcinoma and identify factors associated with OOS. Methods Adult patients un
Autor:
Asif Khalid, Nathan Bahary, Sharon Winters, Lauren Stitt, Adam C. Olson, Richard S. Hoehn, Adam Slivka, Kenneth K. Lee, Ritu Sarkaria, James Ohr, Caroline J. Rieser, Randal E. Brand, Steve Burton, Vikram C. Gorantla, David L. Bartlett, Kenneth E. Fasanella, Jennifer Chennat, Rohit Das, Aatur D. Singhi, Herbert J. Zeh, Anuradha Krishnamurthy, Melissa E. Hogg, John C. Rhee, Susannah G. Ellsworth, Kevin McGrath, Alessandro Paniccia, Amer H. Zureikat
Publikováno v:
Ann Surg Oncol
AIMS: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on
Autor:
M.E. Hogg, Brian A. Boone, Kenneth K. Lee, Alessandro Paniccia, Nathan Bahary, Susannah G. Ellsworth, Amer H. Zureikat, Joal D. Beane, David L. Bartlett, Asmita Chopra, Michael T. Lotze, Aatur D. Singhi, Herbert J. Zeh, Adam C. Olson, Jacob C. Hodges, Steve Burton
Publikováno v:
Ann Surg Oncol
BACKGROUND. Neoadjuvant therapy is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC). It is unknown whether neoadjuvant chemoradiotherapy is more effective than chemotherapy (NCRT vs. NAC). We aim to compare pathological and